Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Immune checkpoint inhibitors, particularly targeting PD-1/PD-L1, have transformed cancer therapy.
• Resistance to single-agent anti-PD-1/PD-L1 therapies limits clinical effectiveness.
• Combination therapies improve response rates but increase adverse events.

Purpose of the Study:

• To review the structure, preclinical basis, and clinical development of multispecific antibodies targeting PD-1/PD-L1.
• To highlight the potential of bispecific, trispecific, and tetra-specific antibodies in cancer treatment.
• To discuss the challenges and future directions for these advanced immunotherapies.

Main Methods:

• Comprehensive literature review of preclinical and clinical studies on multispecific antibodies targeting PD-1/PD-L1.
• Analysis of antibody structure-function relationships and mechanisms of action.
• Evaluation of clinical trial data for approved and investigational multispecific antibodies.

Main Results:

• Several bispecific antibodies (bsAbs) targeting PD-1/PD-L1 are approved or in clinical trials.
• Trispecific antibodies (TsAbs) and tetra-specific antibodies (TetraMabs) are emerging as next-generation therapies.
• Multispecific antibodies demonstrate potential for improved antitumor activity and reduced toxicity.

Conclusions:

• Multispecific antibodies represent a promising therapeutic strategy for overcoming resistance to PD-1/PD-L1 blockade.
• These agents offer a way to enhance efficacy while potentially mitigating the side effects associated with combination therapies.
• Further clinical development is crucial to fully realize the potential of multispecific antibodies in cancer treatment.